Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference

Chief Medical Officer Dr. Michael Chancellor will discuss hemorrhagic cystitis and the company’s lead candidate, LP-10

PITTSBURGH, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc., (Nasdaq: LIPO) ("Lipella," "our," "us" or the "Company"), a pioneering, clinical-stage pharmaceutical company, announced today that Chief Medical Officer Dr. Michael Chancellor will present at the PropThink Digital Investor Conference’s key opinion leader (KOL) discussion on Friday, February 23, 2024, at 2 PM ET. Dr. Chancellor’s presentation will be titled: “Urologist Talks Bladder Cancer and Lasting Side Effects”.

PropThink is a leading online destination for investors seeking insights on publicly-traded, emerging growth companies in the healthcare sector.

Webinar Information:
Date:		Friday, February 23, 2024
Time:		2:00 pm Eastern Time
Register Here:		Urologist Talks Bladder Cancer & Lasting Side Effects
Presenters:		Dr. Michael Chancellor, CMO, Lipella Pharmaceuticals Inc. Deniel Mero, Editor PropThink Conferences (Moderator)

Topic to include:

• the urology community’s view on the surge of interest in bladder cancer.
• the potential of therapies in late-stage development to replace existing, toxic standards of care.
• why hemorrhagic cystitis (HC) is a large, overlooked opportunity and where existing treatments stand.
• the promise of using tacrolimus as treatment for HC.
• Lipella’s expectations for its planned Phase 2b clinical trial evaluating tacrolimus as a treatment for HC.
  

Following the presentation, investors will have an opportunity to ask relevant questions through an interactive Q&A portal. The webcast link will also be posted on the Investors section of Lipella’s company website, and archived following the event. The above listed dates and times are subject to change.